Modified vaccinia Ankara - Bavarian Nordic
Alternative Names: IMVAMUNE; IMVAMUNE® liquid-frozen; IMVAMUNE® freeze-dried; IMVANEX; JYNNEOS; Monkeypox vaccine - Bavarian Nordic; MVA-BN; MVA-BN® Smallpox; MVA-BN® freeze-dried; MVA-BN® liquid-frozen; MVA-BN® smallpox vaccine; Smallpox and monkeypox vaccine - Bavarian NordicLatest Information Update: 09 Apr 2026
At a glance
- Originator Bavarian Nordic
- Developer Bavarian Nordic; Centers for Disease Control and Prevention; Coalition for Epidemic Preparedness Innovations; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA)
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Monkeypox; Smallpox; Vaccinia virus infections
- Phase II Orthopoxvirus infections
Most Recent Events
- 27 Mar 2026 Preregistration for Monkeypox (In children, Prevention) in European Union (SC)
- 27 Mar 2026 Preregistration for Smallpox (In children, Prevention) in European Union (SC)
- 27 Mar 2026 Bavarian Nordic anticipate approval for monkeypox and smallpox vaccine (In children, Prevention) in EMA in 2026